These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 15583451)

  • 1. Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
    Shu E; Matsuno H; Ishisaki A; Kitajima Y; Kozawa O
    Pathophysiol Haemost Thromb; 2003 Jul-2004 Aug; 33(4):206-13. PubMed ID: 15583451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic and hemorrhagic effects of DX-9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants.
    Morishima Y; Tanabe K; Terada Y; Hara T; Kunitada S
    Thromb Haemost; 1997 Nov; 78(5):1366-71. PubMed ID: 9408021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a factor Xa inhibitor, DX-9065a, in a novel rabbit model of venous thrombosis.
    Rogers KL; Chi L; Rapundalo ST; Kramer JB; Gallagher KP
    Basic Res Cardiol; 1999 Feb; 94(1):15-22. PubMed ID: 10097826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor.
    Hara T; Yokoyama A; Morishima Y; Kunitada S
    Thromb Res; 1995 Oct; 80(1):99-104. PubMed ID: 8578544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies.
    Herbert JM; Bernat A; Dol F; Hérault JP; Crépon B; Lormeau JC
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1030-8. PubMed ID: 8786532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
    Graff J; Picard-Willems B; Harder S
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DX-9065a inhibition of factor Xa and the prothrombinase complex: mechanism of inhibition and comparison with therapeutic heparins.
    Rezaie AR
    Thromb Haemost; 2003 Jan; 89(1):112-21. PubMed ID: 12540961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft.
    Kim DI; Kambayashi J; Shibuya T; Sakon M; Kawasaki T
    J Atheroscler Thromb; 1996; 2(2):110-6. PubMed ID: 9225218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin.
    Shimbo D; Osende J; Chen J; Robbins J; Shimoto Y; Kunitada S; Fuster V; Badimon JJ
    Thromb Haemost; 2002 Nov; 88(5):733-8. PubMed ID: 12428086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A synthetic selective inhibitor of factor Xa, DX-9065a, reduces monocyte chemoattractant protein-1 expression after ischemia-reperfusion injury in rat liver.
    Yamaguchi Y; Okabe K; Liang J; Matsumura F; Ohshiro H; Ishihara K; Matsuda T; Takeya M; Kuratsu JI; Mori K; Yamada S; Ogawa M
    Dig Dis Sci; 1999 Dec; 44(12):2568-76. PubMed ID: 10630515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of DX-9065a, an inhibitor of factor Xa, on ellagic acid-induced plantar skin thrombosis assessed in tetrodotoxin- and N(omega)-nitro-L-arginine-treated rats.
    Chino D; Fujita Y; Ishii K; Nakayama K
    J Pharmacol Sci; 2003 Apr; 91(4):319-29. PubMed ID: 12719661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
    Tobu M; Iqbal O; Ma Q; Schultz C; Jeske W; Hoppensteadt D; Lewis B; Fareed D; Fareed J
    Clin Appl Thromb Hemost; 2003 Jan; 9(1):1-17. PubMed ID: 12643318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
    Alexander JH; Yang H; Becker RC; Kodama K; Goodman S; Dyke CK; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Burton JR; Bovill EG; Kawai C; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2005 Mar; 3(3):439-47. PubMed ID: 15748230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
    Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
    J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model.
    Tanabe K; Morishima Y; Shibutani T; Terada Y; Hara T; Shinohara Y; Aoyagi K; Kunitada S; Kondo T
    Thromb Haemost; 1999 May; 81(5):828-34. PubMed ID: 10365760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
    Nishida M; Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
    J Cardiovasc Pharmacol; 2000 Dec; 36(6):770-5. PubMed ID: 11117378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice.
    Matsuno H; Kozawa O; Okada K; Ueshima S; Matsuo O; Uematsu T
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):278-86. PubMed ID: 11791014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.